<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Case Study: Reiker's Palliative Timeline (2018–2026) - Senior Dog Care</title>
    <link rel="stylesheet" href="styles.css">
    <link rel="icon" type="image/svg+xml" href="favicon.svg">
    <meta property="og:title" content="Case Study: Reiker's Palliative Timeline (2018–2026)">
    <meta property="og:description" content="A Real-World Example of Aggressive Palliative Care for Neurodegenerative Disease">
    <meta property="og:image" content="https://hdsheena.github.io/blog/Messenger_creation_793F0F71-5DDC-4624-B5B1-679EBA88FCB0.jpeg">
    <meta property="og:type" content="article">
    <meta property="og:site_name" content="Advocating for Your Senior Dog">
    <meta name="twitter:card" content="summary_large_image">
    <meta name="twitter:title" content="Case Study: Reiker's Palliative Timeline (2018–2026)">
    <meta name="twitter:description" content="A Real-World Example of Aggressive Palliative Care for Neurodegenerative Disease">
    <meta name="twitter:image" content="https://hdsheena.github.io/blog/Messenger_creation_793F0F71-5DDC-4624-B5B1-679EBA88FCB0.jpeg">
</head>
<body>
    <header>
        <div class="container">
            <h1>Case Study: Reiker's Palliative Timeline (2018–2026)</h1>
            <p>A Real-World Example of Aggressive Palliative Care for Neurodegenerative Disease</p>
        </div>
    </header>
    
    <div class="container">
        <div class="breadcrumb">
            <a href="index.html">← Back to Blog Series</a>
        </div>
        
        <article>
            <nav class="table-of-contents">
                <h2>Table of Contents</h2>
                <ul>
                    <li><a href="#phase0">Phase 0: Baseline (2018-2022)</a></li>
                    <li><a href="#phase1">Phase 1: Senior Years (2023-2024)</a></li>
                    <li><a href="#phase2">Phase 2: Aggressive Escalation (2025)</a></li>
                    <li><a href="#phase3">Phase 3: Rollercoaster (Spring-Fall 2025)</a></li>
                    <li><a href="#phase4">Phase 4: Terminal (January 2026)</a></li>
                    <li><a href="#lessons">Clinical Lessons</a></li>
                </ul>
            </nav>
            
            <img src="Messenger_creation_793F0F71-5DDC-4624-B5B1-679EBA88FCB0.jpeg" alt="Reiker, a senior Belgian Malinois with his gray muzzle, being comforted by his owner" class="hero-image">

            <div class="important-box">
                <p><strong>Patient:</strong> Reiker (Belgian Malinois, 15yo)</p>
                <p><strong>Diagnoses:</strong> Neurodegenerative myelopathy (suspected DM), Osteoarthritis, Sarcopenia</p>
                <p><strong>Care Team:</strong> Dr. Andrew Reid & Dr. Fiona Reid (Oriole Road), Dr. Allen Jacobson (Sitara)</p>
                <p><strong>QoL Metric:</strong> "Desire to bite" (Play drive)</p>
            </div>

            <p>Unvarnished timeline of medication, decline, death. Not prescription guide - record of how advocacy bought high-quality years.</p>

            <h2 id="phase0">Phase 0: Baseline Years (2018-2022)</h2>

            <p>Managed for orthopedic maintenance + anxiety. Key: healthy baseline bloodwork = aggressive med options later.</p>

            <ul>
                <li><strong>April 2021 (Lump removal)</strong> - Post-op: Trazodone for activity restriction. Proof: sedation = kindness, not punishment</li>
                <li><strong>July 2022 (Broken canine)</strong> - Pre-dental: 300mg Gabapentin BID + Meloxicam. Geriatric panel "pretty great" = liver/kidneys can handle long-term NSAIDs</li>
            </ul>
            
            <h2 id="phase1">Phase 1: Senior Years (2023-2024)</h2>
            
            <p>Shift to daily management. Trial, assess, pivot.</p>

            <h3>March 2023: Librela Trial</h3>
            <p>Monthly injections for OA.</p>
            <ul>
                <li><strong>Result (July):</strong> "Didn't see effects"</li>
                <li><strong>Lesson:</strong> Failed trial = critical data. Pain not NGF-driven (inflammatory) → suggests neuropathic/central. Stop + pivot</li>
            </ul>
            
            <h3>July 2023: Poly-Pharmacy Begins</h3>
            <ul>
                <li>Gabapentin 300mg daily</li>
                <li>Acetaminophen BID - non-inflammatory pain</li>
                <li>Cartrophen weekly loading</li>
            </ul>
            
            <h2 id="phase1">Phase 1: Senior Years (2023-2024)</h2>
            
            <p>Shift to daily management. Trial, assess, pivot.</p>

            <h3>March 2023: Librela Trial</h3>
            <p>Monthly injections for OA.</p>
            <ul>
                <li><strong>Result (July):</strong> "Didn't see effects"</li>
                <li><strong>Lesson:</strong> Failed trial = critical data. Pain not NGF-driven (inflammatory) → suggests neuropathic/central. Stop + pivot</li>
            </ul>
            
            <h3>July 2023: Poly-Pharmacy Begins</h3>
            <ul>
                <li>Gabapentin 300mg daily</li>
                <li>Acetaminophen BID - non-inflammatory pain</li>
                <li>Cartrophen weekly loading</li>
            </ul>
            
            <h2 id="phase2">Phase 2: Aggressive Escalation (Early 2025)</h2>
            
            <p><strong>February 2025:</strong> Decline in stability (ataxia/knuckling). No "wait and see." Email rapid-fire protocol adjustment.</p>

            <h3>1. Amantadine Pivot (March 2025)</h3>
            <ul>
                <li><strong>March 13 email:</strong> Request Amantadine (NMDA antagonist) for wind-up pain</li>
                <li><strong>Reaction:</strong> Vomiting, acute liquid diarrhea</li>
                <li><strong>Pivot:</strong> Dr. Reid email - pause, treat symptoms, restart lower dose later</li>
                <li><strong>Key:</strong> Adverse event ≠ stop. Pause + recalibrate</li>
            </ul>
            
            <h3>2. Ketamine (Spring 2025)</h3>
            <ul>
                <li><strong>Protocol:</strong> 0.5mg/kg SQ</li>
                <li><strong>May 21 email:</strong> Monthly shots wearing off after 3 weeks. "Try at 14 day mark?"</li>
                <li><strong>Vet:</strong> "No problem q 2 weeks"</li>
                <li><strong>October:</strong> <strong>Weekly</strong> injections to maintain mobility</li>
            </ul>
            
            <div class="key-points">
                <h3>Key Advocacy Moment</h3>
                <p>Email-based adjustment = effective communication. Observed duration, requested frequency change based on functional decline = real-time therapy optimization.</p>
            </div>
            
            <h2 id="phase3">Phase 3: Rollercoaster (Spring-Fall 2025)</h2>

            <ul>
                <li><strong>April 11 crisis:</strong> Low point (GI + ataxia). Euthanasia discussed</li>
                <li><strong>April 12 rally:</strong> "Doing ok!" Near-death dip → rally = classic palliative trajectory. Meds on board (Acetaminophen, Ketamine, Gabapentin) = bounce back for 8 more quality months</li>
            </ul>
            
            <div class="tip-box">
                <h3>The Data (Oct 28, 2025 - Jan 2, 2026)</h3>
                <p>28 tracked days: 22 good, 6 neutral, 0 bad. Objective evidence QoL acceptable this period.</p>
            </div>
            
            <h2 id="phase4">Phase 4: Terminal Phase (January 2026)</h2>
            
            <p>Neurodegeneration overwhelmed pharmacology. "Desire to Bite" metric collapsed.</p>

            <h2 id="phase4">Phase 4: Terminal Phase (January 2026)</h2>

            <p>By January, the neurodegeneration overwhelmed the pharmacological support. The "Desire to Bite" metric—his primary joy—collapsed.</p>

            <h3>January 7, 2026 (The "Hail Mary" Email)</h3>
            <ul>
                <li><strong>Status:</strong> "Lost almost all hind leg function... drag pads-up"</li>
                <li><strong>Proposal:</strong> "Request single dose methadone home trial... If pain shows, at least I'll know"</li>
                <li><strong>Vet:</strong> Agreed. SQ Methadone 0.23ml q8h</li>
                <li><strong>Result:</strong> Profound sedation + comfort, but functional deficits permanent. Pain managed, body gone</li>
            </ul>
            
            <h3>January 10: Metric Failure</h3>
            <ul>
                <li>2/5 (Agree) - "Does not want to play"</li>
                <li>1/5 (Strongly Agree) - "Does not enjoy same activities"</li>
            </ul>
            <p>Primary QoL metric (play drive) consistently failed = decision clear.</p>
            
            <h3>January 13, 2026</h3>
            <p>Euthanized at Oriole Road.</p>

            <div class="important-box">
                <h3>What Bought Time</h3>
                <p>Nearly 1 year after first major "wobble" (Feb 2025). Bought with:</p>
                <ol>
                    <li>Acetaminophen - Cheap, effective, started <em>early</em></li>
                    <li>Ketamine - Heavy hitter for central sensitization, owner-adjusted frequency</li>
                    <li>Communication - Email adjustments (Amantadine, Methadone) = immediate diagnostics</li>
                    <li>Tracking - Good/bad day calendars = data, not emotion</li>
                    <li>Clear metrics - "Desire to bite" = objective endpoint</li>
                </ol>
            </div>
            
            <h2 id="lessons">Clinical Lessons</h2>
            
            <h3>1. Failed Trials = Data</h3>
            <p>Librela "failed" but gave critical info about pain nature. Unsuccessful trials narrow diagnostic field.</p>
            
            <h3>2. Email Protocol Adjustments Work</h3>
            <p>Ketamine frequency + amantadine troubleshooting via email. Reduced visits/stress, real-time optimization based on owner observation.</p>
            
            <h3>3. Diagnostic Trial</h3>
            <p>Methadone at end = diagnostic tool differentiating pain from neuro decline. Function didn't improve despite analgesia = answer obtained.</p>
            
            <h3>4. Define QoL in Advance</h3>
            <p>Reiker: "Desire to bite." Others: greeting family, eating, sleeping comfortably. Define early, track objectively. See <a href="quality-of-life-assessments.html">QoL Assessments</a> for tools.</p>
            
            <figure class="quality-metric-figure">
                <img src="Messenger_creation_7D28A537-ABE6-4BA1-83A8-DB65A87DD732.jpeg" alt="Reiker engaging with his favorite activity - demonstrating his 'desire to bite' metric">
                <figcaption class="memorial-caption">Reiker demonstrating his "Desire to bite" - the primary quality-of-life metric we tracked throughout his palliative journey.</figcaption>
            </figure>
            
            <h3>5. Aggressive ≠ Inappropriate</h3>
            <p>Weekly ketamine, daily acetaminophen, multiple NMDA antagonist trials. Not reckless = systematic, monitored, function-based. Aggressive palliative care (properly managed) extends quality time, not just survival.</p>
            
            <div class="warning-box">
                <h3>Not a Prescription</h3>
                <p>Every case different. Reiker's protocol for <em>his</em> presentation: neurodegenerative with preserved mentation, declining motor. Your dog's situation/bloodwork/comorbidities/QoL metrics will differ. Use as advocacy/communication framework, not medication checklist.</p>
            </div>
            
            <h2>How to Use This Case</h2>
            <ol>
                <li>Establish baseline bloodwork - Healthy organs = more options later</li>
                <li>Track good vs. bad days - Calendar/app (HosPet) for objective data</li>
                <li>Define metric - What activity/behavior non-negotiable for QoL?</li>
                <li>Communicate frequently - Email observations. Good vets appreciate data-driven owners</li>
                <li>Trial + pivot - Med doesn't work? Stop, move on. Failed trials = useful info</li>
                <li>Know when to stop - Primary metric fails consistently = honor dog by letting go. See <a href="end-of-life-planning.html">End-of-Life Planning</a>.</li>
            </ol>
            
            <p>Aggressive advocacy, systematic medication management, peaceful end when function irretrievable. Not perfect, but <em>data-driven</em> = clearer hard decisions.</p>

            <div class="navigation">
                <a href="index.html" class="nav-button back">← Back to Series</a>
            </div>
        </article>
    </div>
    
    <footer>
        <p>&copy; 2026 Senior Dog Care Resources. In memory of Reiker (2011-2026).</p>
    </footer>
</body>
</html>
